A prospective, randomised, double-blind, multicentre, phase III clinical study on transarterial chemoembolisation (TACE) combined with sorafenib vs TACE plus placebo in patients with hepatocellular cancer (HCC) before liver transplantation (LTx) – Heidelberg Liver Cancer Study (HeiLivCa Study).

Trial Profile

A prospective, randomised, double-blind, multicentre, phase III clinical study on transarterial chemoembolisation (TACE) combined with sorafenib vs TACE plus placebo in patients with hepatocellular cancer (HCC) before liver transplantation (LTx) – Heidelberg Liver Cancer Study (HeiLivCa Study).

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2015

At a glance

  • Drugs Sorafenib (Primary) ; Carboplatin; Carboplatin
  • Indications Liver cancer
  • Focus Adverse reactions; Biomarker; Registrational; Therapeutic Use
  • Acronyms HeiLivCa
  • Most Recent Events

    • 01 Jun 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
    • 10 Jul 2012 50 patients have been recruited to date, as reported by ISRCTN: Current Controlled Trials record.
    • 14 Apr 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2008-002269-29).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top